Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy

Israel Medical Association Journal

Volumn 15, Issue 1, 2013, Pages 23-26

  Ashkenazi Hoffnung, Liat ^a   Merlob, Paul ^a,b   Stahl, Bracha ^a   Klinger, Gil ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Doxylamine; Nausea and vomiting of pregnancy (NVP); Pyridoxine

Indexed keywords

BENDECTIN; CEFALEXIN; CEFTRIAXONE; DEBENDOX; DIMENHYDRINATE; DOXYLAMINE PLUS PYRIDOXINE; METOCLOPRAMIDE; OSELTAMIVIR; SERTRALINE; SICLECTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PREGNANCY DISORDER; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYLAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; NAUSEA; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; PYRIDOXINE; QUESTIONNAIRES; TREATMENT OUTCOME; VITAMIN B COMPLEX; VOMITING;

EID: 84873519181     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Koren G, Levichek Z. The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. Am J Obstet Gynecol 2002; 186: S248-52.
2. Fell DB, Dodds L, Joseph KS, Allen VM, Butler B. Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. Obstet Gynecol 2006; 107: 227-84.
3. Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Determinants of early medical management of nausea and vomiting of pregnancy. Birth 2009; 36 (1): 70-7.
4. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 (16): 1128-37.
5. Ornstein M, einarson A, Koren G. Bendectin/Diclectin for morning sickness: a Canadian follow-up of an American tragedy. Reprod Toxicol 1995; 9 (1): 1-6.
6. Brent R. Bendectin and birth defects. Hopefully, the final chapter. Birth Defects Res A Clin Mol Teratol 2003; 67 (2): 79-87.
7. ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy Obstet Gynecol 2004; 103 (4): 803-14.
8. Nulman I, Koren G. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. Can J Clin Pharmacol 2009; 16 (3): e400-6.
9. Baggley A, Navioz Y, Maltepe C, Koren G, Einarson A. Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically. J Midwifery Womens Health 2004; 49 (4): 350-4.
10. Magee LA, Mazzotta P, Koren G. evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002; 186 (5 Suppl Understanding): S256-61.
11. Boskovic R, einarson A, Maltepe C, Wolpin J, Koren G. Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. J Obstet Gynaecol Can 2003; 25 (10): 830-3.
12. Koren G, Clark S, Hankins GDV, et al. effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 2010; 203: 571.e1-7.
13. Quinla JD, Hill DA. Nausea and vomiting of pregnancy. Am Fam Physician 2003; 68 (1): 121-8.
14. King TL, Murphy PA. evidence-based approaches to managing nausea and vomiting in early pregnancy. J Midwifery Womens Health 2009; 54 (6): 430-44.
15. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol 2001; 41 (8): 842-5.